In patients with tumor PD-L1 ≥ 1%, median (95% CI) PFS was 24.0 (5.6–55.5) months with nivolumab plus ipilimumab versus 6.7 (4.3–8.3) months with chemotherapy (HR 0.55; 95% CI, 0.32–0.95); 5-year PFS rate was 33% versus 11% (Fig. 2A). Here, CD274 is linked to neoplasm.